Search results
We look forward to your inquiries and will be glad to answer all your questions: Univ.-Prof. Dr. med. Pavel Strnad. Lead Consultant and Scientific Advisor of the Alpha1-Liver Network and patient advocacy group Alpha1-Deutschland e.V. pstrnad ukaachen de. Dr. med. Malin Fromme. Resident physician.
6 days ago · Strnad explains the need for noninvasive biomarkers in AATD liver disease and early research about circulating Z-polymer’s potential association with clinically relevant adverse outcomes.
Aug 5, 2024 · Pavel Strnad, MD: Fazirsiran’s Potential in AATD-Associated Liver Disease. Strnad explains how findings from the SEQUOIA study inform fazirsiran’s use in patients with AATD-associated liver disease and its further evaluation in future phase 3 trials.
12 hours ago · Pavel Strnad, MD: Considerations for Safe Alcohol Consumption in AATD. August 22, 2024. By Abigail Brooks, MA. News. Video. Strnad explains how although moderate alcohol consumption is likely tolerable in most individuals with AATD, careful monitoring of liver-related parameters is still important.
Jan 5, 2021 · Pavel Strnad is a full professor and leading physician at the University Hospital Aachen, Germany. In 2016, he was named one of the Rising Stars of the United European Gastroenterology.
Pavel STRNAD | Cited by 12,029 | of University Hospital RWTH Aachen, Aachen | Read 404 publications | Contact Pavel STRNAD.
Correspondence to Pavel Strnad, MD, Coordinating Center for Alpha1-antitrypsin Deficiency-related Liver Disease of the European Reference Network (ERN) ‘Rare Liver’ and the European Association for the Study of the Liver (EASL) registry group ‘Alpha1-Liver’, University Hospital Aachen, Pauwelsstr. 30, 52074 Aachen, Germany.
